Manuel Litchman
Chief Executive Officer at MUSTANG BIO, INC.
Net worth: 44 738 $ as of 29/04/2024
Network origin in Manuel Litchman first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 23 | |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ.
15
| Subsidiary | Pharmaceuticals: Major | 15 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Manuel Litchman via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Director/Board Member | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| TG THERAPEUTICS, INC. | Pharmaceuticals: Major | Founder Chief Executive Officer Director/Board Member | |
| NATIONAL HOLDINGS CORPORATION | Investment Banks/Brokers | Chairman Director/Board Member | |
| SANGAMO THERAPEUTICS, INC. | Biotechnology | Director of Finance/CFO | |
| KERYX BIOPHARMACEUTICALS | Pharmaceuticals: Major | Founder Chief Executive Officer | |
| BRAINSTORM CELL THERAPEUTICS INC. | Biotechnology | Director/Board Member Chief Tech/Sci/R&D Officer | |
Novartis Oncology, Inc.
 Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Novartis Oncology, Inc. provides healthcare solutions. The firm offers medicines, eye care and generic pharmaceuticals. It also offers patient declaration, patient support and assistance, and additional resources. The company is headquartered in East Hanover, NJ. | Pharmaceuticals: Major | Director of Finance/CFO President | |
Novartis Corp.
 Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Pharmaceuticals: Major | Director of Finance/CFO President | |
| FORTRESS BIOTECH, INC. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Comptroller/Controller/Auditor | |
Venatorx Pharmaceuticals, Inc.
 Venatorx Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Venatorx Pharmaceuticals, Inc. develops novel anti-infective agents to address the threat of antibiotic resistance. It offers antibiotic resistant bacteria and Carbapenem-resistant Enterobacteriaceae a family of gram-negative bacteria that are resistant to all known ?-lactam antibiotics, including penicillins, cephalosporins, monobactams, and carbapenems. The company was founded by Christopher J. Burns, Luigi Xerri, and Daniel Pevear in 2010 and is headquartered in Malvern, PA. | Miscellaneous Commercial Services | Director/Board Member | |
| NOVARTIS AG | Pharmaceuticals: Major | Corporate Officer/Principal Chief Operating Officer | |
| University of Virginia | College/University | Undergraduate Degree Graduate Degree | |
Sangamo Therapeutics UK Ltd.
 Sangamo Therapeutics UK Ltd. Miscellaneous Commercial ServicesCommercial Services Sangamo Therapeutics UK Ltd. researches and develops transcription factors in the regulation of genes. The company was founded on April 21, 1999 and is headquartered in Cheltenham, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
| State University of New York at Albany | College/University | Undergraduate Degree Undergraduate Degree | |
| University of California, Berkeley | College/University | Undergraduate Degree | |
| University of Michigan | College/University | Masters Business Admin | |
| Yeshiva University | College/University | Undergraduate Degree Undergraduate Degree | |
| Baruch College | College/University | Undergraduate Degree Undergraduate Degree | |
The New York City Investment Fund Manager, Inc.
 The New York City Investment Fund Manager, Inc. Investment ManagersFinance The New York City Investment Fund Manager Inc. (The New York City Investment Fund Manager) is a venture capital firm founded by Henry Kravis in 1996. The firm is headquartered in New York, United States. | Investment Managers | Consultant / Advisor | |
engeneOS, Inc.
 engeneOS, Inc. Miscellaneous Commercial ServicesCommercial Services EngeneOS, Inc. provides research and development services. The private company is based in Waltham, MA. The company was founded by John Schwartz. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Opus Point Partners Management LLC
 Opus Point Partners Management LLC Investment ManagersFinance Opus Point Partners Management LLC (OPPM) is a hedge fund manager headquartered in New York City. The firm was founded by Lindsay Rosenwald and Michael Weiss in 2009. They are owned by Opus Point Partners LLC, which is a subsidiary of Weiss & Co. LLC. OPPM manages investments that are dedicated to healthcare and life science. | Investment Managers | Chief Executive Officer Founder | |
| Columbia Law School | College/University | Graduate Degree Graduate Degree | |
| Columbia Business School | College/University | Masters Business Admin | |
| ORIGO ACQUISITION CORP | Financial Conglomerates | Chief Executive Officer Chairman Director/Board Member Director/Board Member | |
Highline Therapeutics, Inc.
 Highline Therapeutics, Inc. BiotechnologyHealth Technology Part of Versant Venture Management LLC, Highline Therapeutics, Inc. operates as a biotech incubator. The private company is based in New York, NY. | Biotechnology | Chief Executive Officer | |
| CHECKPOINT THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Chairman Director of Finance/CFO Director/Board Member Investor Relations Contact | |
| AVENUE THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director of Finance/CFO Director/Board Member Investor Relations Contact | |
Helocyte, Inc.
 Helocyte, Inc. Miscellaneous Commercial ServicesCommercial Services Helocyte, Inc. engages in the development and commercialization of immunotherapies for the prevention and treatment of cytomegalovirus or CMV (cancer and infectious disease). It focuses on developing PepVax, a HLA-restricted single antigen peptide vaccine for controlling CMV in allogeneic hematopoietic stem cell transplant recipients and Triplex. The company was founded by Donald J. Diamond in 2015 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Founder Director/Board Member | |
Cyprium Therapeutics, Inc.
 Cyprium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Fortress Biotech, Inc., Cyprium Therapeutics, Inc. is an American New York-based company focused on developing novel therapies for the treatment of Menkes disease and related copper metabolism disorders. The private company was granted FDA breakthrough therapy, fast track, and rare pediatric disease designations, as well as FDA orphan drug designation for both Cutx-101 and AAV-ATP7A. The European Medicines Agency also granted orphan drug designation to Cyprium. In March 2017, Cyprium entered into a cooperative research and development agreement with the Eunice Kennedy Shriver National Institute of Child Health and Human Development to advance the clinical development of Cutx-101 for the treatment of Menkes disease. In 2023, Cyprium completed the transfer of its proprietary rights and assigned its FDA documents pertaining to Cutx-101 to Sentynl Therapeutics, Inc. Cyprium and NICHD also previously entered into a worldwide, exclusive license agreement to develop and commercialize AAV-ATP7A gene therapy, which is currently in pre-clinical development. The company was founded in 2017 by Michael Sean Weiss, Lindsay Allan Rosenwald, and Lung S. Yam, who has been the CEO since then. | Miscellaneous Commercial Services | Founder Founder | |
| Cellvation, Inc. | Chairman Director/Board Member | ||
| JOURNEY MEDICAL CORPORATION | Pharmaceuticals: Major | Chairman Director/Board Member Investor Relations Contact | |
Caelum Biosciences, Inc.
 Caelum Biosciences, Inc. BiotechnologyHealth Technology Caelum Biosciences, Inc. operates as a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. The company was founded in January 2017 and is headquartered in New York, NY. | Biotechnology | Director/Board Member Director/Board Member | |
Pandion Operations, Inc.
 Pandion Operations, Inc. Miscellaneous Commercial ServicesCommercial Services Pandion Operations, Inc. develops drugs for autoimmune, inflammatory, and transplant indications. The company was founded by Anthony J. Coyle, Jo Viney, Alan Crane, and David Sachs in 2017 and is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Director/Board Member | |
| THESEUS PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member | |
| Deirdres House | Director/Board Member Director/Board Member | ||
Gotham Therapeutics Corp.
 Gotham Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Gotham Therapeutics Corp. develops and manufactures pharmaceutical medicines. The firm develops new treatment options for patients suffering from cancers, auto-immune and neurodegenerative diseases. The company was founded by Samie Jaffrey in 2017 and is headquartered in New York, NY. | Pharmaceuticals: Major | Director/Board Member | |
| CENTURY THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
858 Therapeutics, Inc.
 858 Therapeutics, Inc. BiotechnologyHealth Technology 858 Therapeutics, Inc. operates as a pharmaceutical company. The company was founded in 2019 and is headquartered in San Diego, CA. | Biotechnology | Director/Board Member | |
| PANDION THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Baergic Bio, Inc.
 Baergic Bio, Inc. Pharmaceuticals: MajorHealth Technology Baergic Bio, Inc. develops therapeutic drugs for the treatment of central nervous system disorders. It offers oncology, rare diseases, and gene therapy. The company is headquartered in New York, NY. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| CEREVEL THERAPEUTICS HOLDINGS, INC. | Pharmaceuticals: Major | Director of Finance/CFO | |
| Boston University School of Medicine | College/University | Doctorate Degree Doctorate Degree | |
Stablix, Inc.
 Stablix, Inc. Miscellaneous Commercial ServicesCommercial Services Stablix, Inc. is a biotechnology company based in New York, NY. The company is focused on establishing a new paradigm for tackling diverse diseases by harnessing the power of the body's own cellular machinery through targeted protein stabilization. Stablix's restored™ platform generates heterobifunctional small molecules (restoracs™) that selectively recruit active deubiquitinases (dubs) to target proteins for precise removal of ubiquitin to restore protein function. The company is currently advancing its lead programs towards clinical studies. The company's platform is based on the work of Henry Colecraft, Ph.D., professor of physiology and cellular biophysics, and professor of pharmacology, Columbia University Irving Medical Center. Stablix was founded in June 2021 with a $63 million series A led by founding investor Versant Ventures with New Enterprise Associates (NEA), Cormorant Asset Management, Euclidean Capital, and Alexandria Venture Investments. Stuart Anthony Kingsley has been the CEO of the company since 2022. | Miscellaneous Commercial Services | Director/Board Member | |
| FirstLight Bio, Inc. | President | ||
Affini-T Therapeutics, Inc.
 Affini-T Therapeutics, Inc. BiotechnologyHealth Technology Affini-T Therapeutics, Inc. is a biotechnology company based in Watertown, MA. Affini-t is focused on developing potentially curative therapies for solid tumor cancers by unlocking the power of T cells and targeting core oncogenic drivers. The company's differentiated cell therapy platform harnesses state-of-the-art engineering and synthetic biology capabilities to optimize T cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. The company is targeting Kras and other oncogenic and viral driver mutations to open a new and differentiated target space, thereby minimizing the risk of cancer. The company was founded by Jak Knowles and Arjun Goyal, with Jak Knowles serving as the CEO since incorporation. | Biotechnology | Chief Operating Officer |
Statistics
International
| United States | 48 |
| Switzerland | 2 |
| United Kingdom | 2 |
Sectoral
| Health Technology | 26 |
| Consumer Services | 10 |
| Commercial Services | 8 |
| Finance | 6 |
Operational
| Director/Board Member | 94 |
| Corporate Officer/Principal | 80 |
| Director of Finance/CFO | 47 |
| Independent Dir/Board Member | 32 |
| Undergraduate Degree | 29 |
Most connected contacts
| Insiders | |
|---|---|
| Michael Weiss | 25 |
| Lindsay Rosenwald | 23 |
| Anthony Adam Rosenberg | 23 |
| Neil Herskowitz | 22 |
| Carlo Rizzuto | 22 |
| David J. Horin | 18 |
| Eliot Lurier | 13 |
| Mary Coelho | 12 |
| Dagmar Rosa-Bjorkeson | 12 |
| Herve Hoppenot | 11 |
| Adam Chill | 11 |
| Cathryn Clary | 11 |
| Ralph Niven | 10 |
| Meryl Zausner | 10 |
| Kathy Yi | 9 |
- Stock Market
- Insiders
- Manuel Litchman
- Company connections
